- Design
- Consensus report based on systematic examination of evidence since 2022
- Population
- Non-pregnant adults with type 2 diabetes
- Primary outcome
- Recommendations for holistic management and long-term outcomes
- Effect
- Earlier SGLT2i and/or GLP-1-based therapy, potentially from diagnosis; earlier combination with CVD, CKD or HF
The ADA and EASD joint consensus on type 2 diabetes in non-pregnant adults, last updated in 2022, was published in Diabetes Care on 2 October. It is a consensus report built on a systematic review of evidence since 2022, not a single trial.
The central shift is from managing glucose to protecting organs. The report advocates earlier use of SGLT2 inhibitors and/or GLP-1-based therapies, potentially from diagnosis, for long-term outcomes. It says combining the two should be considered earlier in people who also have cardiovascular disease, chronic kidney disease or heart failure. Lifestyle (including sleep and the full 24-hour activity pattern), psychological support and weight management are framed as foundations rather than a first step to be passed through.
For Indian practice the barrier is cost rather than evidence. Generic dapagliflozin and empagliflozin are widely available and inexpensive; GLP-1-based drugs remain costly. The consensus's own emphasis on equitable implementation points to starting with what a patient can sustain. Indian guidance (RSSDI) has not been reviewed here, and this report does not replace it.
- At diagnosis, assess cardiovascular disease, kidney function, albuminuria and heart failure before choosing the first agent.
- In type 2 diabetes with CKD, heart failure or atherosclerotic disease, consider an SGLT2 inhibitor early, independent of HbA1c.
- Where cardiovascular, renal or heart failure disease coexist, consider adding a GLP-1-based drug to an SGLT2 inhibitor rather than choosing one.
- Ask about sleep, smoking and mood as part of the core review, not as extras.
- Where cost limits choice, an inexpensive generic SGLT2 inhibitor still delivers much of the organ protection the report emphasises.
Why it matters
It moves the default first-line decision from what lowers glucose cheapest to what protects heart and kidney earliest.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free